You are here: Home » 2021 » Archives for January 2021

CNH Industrial completes the acquisition of four divisions of CEG in South Africa

CNH Industrial completes the acquisition of four businesses of Capital Equipment Group (CEG). This transaction will enable the Company to expand its direct distribution network in southern Africa and drive continuous development of new and improved services for our customers in the region.

LUGANO, Switzerland, Jan. 12, 2021 (GLOBE NEWSWIRE) — CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announces that it has successfully concluded the deal to acquire the four businesses from CEG, a business unit of Humulani Marketing Pty Ltd, ultimately owned by Invicta Holdings Limited. The businesses to be acquired from CEG are: Case IH distributor Northmec; CASE Construction Equipment distributor CSE; spare parts distributor NHSA; and spare parts and implements distributor Landboupart.

While these four divisions will continue to do business under their established market identities, they are now an integral part of CNH Industrial and will continue to support the Company's dealer network and end users with their in–depth and longstanding knowledge of the local market.

The transaction enables CNH Industrial to consolidate the distribution of Case IH Agriculture, CASE Construction equipment and aftermarket services in South Africa. It will allow the Company to provide an enhanced customer experience throughout the entire pre–and–after sales cycle, and strengthen its position to further develop its presence in the region.

"The Republic of South Africa is one of the most important markets for CNH Industrial on the Continent. This investment is testament to our confidence in the agriculture and construction markets' potential. It also speaks to our commitment to growth in the Country, as well as across the wider southern Africa region," said Federico Bellotto, Head of Agriculture and Construction, CNH Industrial South Africa and Southern African Customs Union. "The new consolidated distribution and service structure will enable us to be more agile and responsive to the specific needs of local customers, strengthening all–round support and ensuring our product offering perfectly matches their specific requirements."

Sign up for news alerts from CNH Industrial and its brands on the CNH Industrial AMEA & ANZ Newsroom: media.cnhindustrial.com/AMEAANZ–ENGLISH/Subscribe

CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) is a global leader in the capital goods sector with established industrial experience, a wide range of products and a worldwide presence. Each of the individual brands belonging to the Company is a major international force in its specific industrial sector: Case IH, New Holland Agriculture and Steyr for tractors and agricultural machinery; Case and New Holland Construction for earth moving equipment; Iveco for commercial vehicles; Iveco Bus and Heuliez Bus for buses and coaches; Iveco Astra for quarry and construction vehicles; Magirus for firefighting vehicles; Iveco Defence Vehicles for defence and civil protection; and FPT Industrial for engines and transmissions. More information can be found on the corporate website: www.cnhindustrial.com

Media contacts:

Nan Nie
Corporate Communications Manager AMEA & ANZ
Tel: +86 21 2082 2201
E–mail: media.amea@cnhind.com


GLOBENEWSWIRE (Distribution ID 8124243)

ATS Appoints Wencor as Exclusive Global Distributor of PMA Portfolio

Agreement also includes the EverLatch Cargo Door Latch, an STC–derived PMA product targeted at improving airline performance and reducing maintenance costs

EVERETT, Wash., Jan. 11, 2021 (GLOBE NEWSWIRE) — ATS (Aviation Technical Services) today announced an agreement with Wencor as sole distributor of its Part Manufacturer Approval (PMA) product line, approved by the FAA under ATSMRO part number references. Included in the agreement is the ATS–patented EverLatch Cargo Door Latch, a cost–effective solution designed to enhance reliability of Boeing 737NG aircraft. The arrangement targets the worldwide commercial aviation aftermarket and extends through December 2025.

Engineered utilizing data from airframe maintenance and component repair workscopes, ATS PMAs replace high cost, long lead time, and high failure parts. "Our PMA Program started through collaboration with one of our heavy maintenance customers and has been successful in identifying millions of dollars in savings for Boeing 737 operators," stated Brian Olsen, ATS President of Component and Engineering Solutions. "We are looking forward to increasing the program's exposure to airlines and MROs through Wencor's established channels."

"We are excited to continue to build our relationship with ATS and add their PMAs to our industry leading portfolio which now includes greater than 11,000 alternative material solutions. As the aviation industry continues to bounce back, Wencor remains committed more than ever to providing innovative solutions to our customers that enable reliability, availability and cost efficiencies. Partnering with ATS to expand our offering enhances that objective" said Wencor Chief Executive Officer Shawn Trogdon.

About ATS:
For 50 years, ATS has been providing industry–leading, comprehensive MRO and support services for commercial and military aircraft. We are focused on making the MRO process better through reducing span times, increasing mechanic efficiency, improving airline operational performance, and lowering overall costs through maintenance prevention strategies.

ATS offerings include:

  • Airframe Services: Heavy maintenance and modification
  • Component Repair: Providing repair and rotable exchange options for accessories, composites, electrical and fuel components, flight control surfaces, hydraulics, pneumatics and structures
  • Engineering Solutions: PMA parts, STC offerings, as well as design and repair engineering
  • Ranger Asset Management: Component part sales, consignment, and inventory distribution services available for virtually every commercial airframe and engine platform. Also includes asset acquisition and teardown activities

For more information, please visit: atsmro.com, follow @atsmrotech on Twitter, and join ATS on Facebook and LinkedIn.

About Wencor
Wencor has been a trusted partner in aerospace for over 60 years, offering CMM and DER repairs, PMA and an extensive network of distribution solutions to help make flights safer and more cost effective. We support most of the commercial airlines, repair stations and OEMs worldwide through our corporate affiliates Wencor, Soundair Aviation Services, PHS/MWA Aviation Services, Absolute Aviation Services, Aerospace Coatings International, Flight Line Products, Accessory Technologies Corporation, Fortner Engineering & Manufacturing, Silver Wings Aerospace, and Kitco Defense. Wencor Group is headquartered in the Atlanta, Georgia area with additional offices in Utah, Miami, Seattle, California, Alabama, New York, Amsterdam, Singapore, Shanghai, and Istanbul. For more information, please visit wencor.com, follow @Wencor_Official on Twitter, and join Wencor on LinkedIn.

Contacts:
ATS
Sherry Cole Bergstrom
Director of Marketing, PR and Communications
+1 425 423 3037
sherry.bergstrom@atsmro.com		 WENCOR
sales@wencor.com
+1–678–490–0140
AOG: +1–888–864–0462


GLOBENEWSWIRE (Distribution ID 8123827)

Entera Bio Issues Letter to Shareholders

BOSTON and JERUSALEM, Jan. 11, 2021 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today issued a Letter to Shareholders from Spiros Jamas, Sc.D, its newly appointed Chief Executive Officer and a member of its Board of Directors.

Dear Shareholders,

We hope you and your family have fared well and been healthy during a difficult 2020. As we begin the new year, we are hopeful the global community, with a little help from the biopharmaceutical industry, will overcome the most significant pandemic in a century. Personally, I am thrilled to start 2021 leading Entera and its highly promising oral protein drug delivery platform through advanced clinical trials with the hope of giving patients a much–needed oral alternative to treatments currently delivered via injection. I believe that Entera's platform can be used to establish multiple partnering opportunities to generate funding and allow the Company to share in the future value of de–risked assets. Working with the talented team here, there is much we will accomplish together from both a clinical and corporate perspective.

Strong balance sheet to drive business objectives

Entera strengthened its balance sheet at December 31, 2020 to approximately $8.6 million in cash and cash equivalents with the addition of $3.2 million in proceeds raised in the fourth quarter through a previously filed at–the–market equity program. This funds the Company's clinical programs and operations into the third quarter of 2021. At December 31, 2020, Entera had 21.1 million primary shares outstanding.

EB613 "" Oral PTH to treat patients with osteoporosis

We recently completed enrollment in the Israeli Phase 2 clinical trial and received U.S. Food and Drug Administration approval for our Investigational New Drug (IND) application for our lead program EB613, an orally delivered human parathyroid hormone (1–34) (PTH), for the treatment of osteoporosis. The FDA's approval of our IND clears Entera to proceed with our initial planned U.S. clinical trial of EB613, which is positioned as the first potential drug candidate that could provide a patient friendly, once daily, oral, bone building (anabolic) treatment for osteoporosis patients.

Having announced positive interim bone mineral density (BMD) data in the Phase 2 EB613 study, we anticipate reporting interim biomarker data; and final biomarker, BMD and safety results; in the first and second quarters of 2021, respectively. Assuming positive final results from the current Phase 2 trial, we plan to advance EB613 into a pivotal Phase 3 trial that could commence patient enrollment in 2022. Our current plan is to utilize the 505(b)(2) regulatory pathway for EB613 requiring a single pivotal non–inferiority study compared to Forteo , the leading daily injectable PTH with an estimated $1.4 billion in annual sales.

Today's osteoporosis market is characterized by high prevalence that is greatly underdiagnosed and undertreated. Only an estimated 5% of osteoporosis patients, those with severe disease, receive treatment today. As a result, the current global market for injectable PTH, the standard of care for severe osteoporosis, is $4 billion. Based on a recent market analysis, we are highly encouraged about EB613's potential to improve the quality of life for many of the estimated 200 million people living with osteoporosis worldwide. If we are able to demonstrate that EB613 is as safe and effective as injectable PTH, we believe we will increase the market size by offering a more patient friendly, pain–free, and lower cost alternative to currently marketed injectable products and potentially grow the total addressable market to $20 billion by treating all osteoporosis patients.

A vast majority of doctors surveyed in the U.S., Europe, and Japan indicated oral PTH would be their preferred method of treatment for severe osteoporosis patients relative to other options. Moreover, they indicated they would likely increase prescribing levels for osteoporosis patients if an effective oral PTH treatment is available. Data from the market analysis show the potential of EB613 to have a transformative impact on the treatment of osteoporosis by serving as a possible first line therapy that enables doctors to treat patients with moderate to severe osteoporosis who are currently untreated due to the constraints associated with injectable PTH.

Beyond the convenience of oral administration and the elimination of pain associated with needles, EB613 also delivers a cost advantage that may be particularly important to insurers and patients alike. Entera has refined its scalable drug production process, reducing the cost per pill to enable a price point considerably lower than currently marketed injectable products.

Oral PTH to treat hypoparathyroidism, an orphan disease

EB612, an oral PTH for the treatment of hypoparathyroidism, successfully met the primary and secondary endpoints in a Phase 2a clinical trial. Hypoparathyroidism, for which EB612 was granted orphan drug designation in the U.S. and Europe, is a rare condition in which a person produces an abnormally low level of PTH, causing a heavy disease burden due to its impact on a patient's cardiovascular, neurologic, renal, and skeletal systems. There is a clear unmet medical need for a safe and effective treatment for the estimated 60,000 insured hypoparathyroidism patients in the U.S., as Natpara , the one drug currently approved by the FDA for this indication, was recalled in 2019 and has only recently been reintroduced to a limited number of those patients due to supply issues. Furthermore, this drug is likely to be used in only the most severe patients due to its potential risk of bone cancer in animal studies.

Platform technology

We believe our platform technology has the potential for use in approximately one third of all large molecule therapeutics. Our platform involves the simulation of the pharmacokinetic profile of target molecules, the development of specific formulations using our proprietary 2–component system and subsequent confirmation of activity in preclinical studies. Our product candidates, EB613 and EB612, serve as the initial validation of the platform and we are evaluating additional research programs that have potential applications in a number of indications that are either currently treated via injectables or untreated. Additionally, our highly productive collaboration with Amgen involving an undisclosed anti–inflammatory target is continuing and Amgen has completed several studies to evaluate different formulations of its drug using Entera's technology.

As a substantial percentage of FDA approved drugs each year are injectable biologics, we see a significant opportunity for Entera's platform technology to deliver these approved products in oral form. While we work to execute on these opportunities, I look forward to a highly productive year with frequent communications with our shareholders. We thank all of you for your ongoing support of Entera as we continue our focused pursuit to improve patients' lives. We wish you a healthy, prosperous, and happy 2021.

Spiros Jamas, Sc.D

Chief Executive Officer and Director

About Entera Bio

Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.

Forward Looking Statements

Various statements in this release are "forward–looking statements" under the securities laws. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera's forward–looking statements include, among others: changes in our interpretation of the interim data from the ongoing Phase 2 clinical trial of EB613, the timing of data readouts from the ongoing Phase 2 clinical trial of EB613, unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; a possible suspension of the Phase 2 clinical trial of EB613 for clinical or data–related reasons; the impact of COVID–19 on Entera's business operations including the ability to collect the necessary data from the Phase 2 trial of EB613; the potential disruption and delay of manufacturing supply chains, loss of available workforce resources, either by Entera or its collaboration and laboratory partners, due to travel restrictions, lay–offs or forced closures or repurposing of hospital facilities; impacts to research and development or clinical activities that Entera is contractually obligated to provide, such as those pursuant to Entera's agreement with Amgen; overall regulatory timelines, if the FDA or other authorities are closed for prolonged periods, choose to allocate resources to review of COVID–19 related drugs or believe that the amount of Phase 2 clinical data collected are insufficient to initiate a Phase 3 trial, or a meaningful deterioration of the current political, legal and regulatory situation in Israel or the United States; the availability, quality and timing of the data from the Phase 2 clinical trial of EB613 in osteoporosis patients; the ability to find a dose that demonstrates the comparability of EB613 to FORTEO in the ongoing Phase 2 clinical trial of EB613; the size and growth of the potential market for EB613 and Entera's other product candidates including any possible expansion of the market if an orally delivered option is available in addition to an injectable formulation; the scope, progress and costs of developing Entera's product candidates; Entera's reliance on third parties to conduct its clinical trials; Entera's expectations regarding licensing, business transactions and strategic collaborations; Entera's operation as a development stage company with limited operating history; Entera's ability to continue as a going concern absent access to sources of liquidity; Entera's expectations regarding its expenses, revenue, cash resources, including the amount of cash and cash equivalents as of December 31, 2020 referenced above, which has not been audited or reviewed by Entera's independent registered public accounting firm and should be viewed in the context of all other available information regarding Entera's results of operations, liquidity and financial condition; Entera's ability to raise additional capital; Entera's interpretation of FDA feedback and guidance and how such guidance may impact its clinical development plans; Entera's ability to obtain and maintain regulatory approval for any of its product candidates; Entera's ability to comply with Nasdaq's minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera's intellectual property position and its ability to protect its intellectual property; and other factors that are described in the "Special Note Regarding Forward–Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Entera's annual and current filings which are on file with the SEC and available free of charge on the SEC's website at http://www.sec.gov. Additional factors may be set forth in those sections of Entera's Quarterly Report on Form 6–K for the quarter ended September 30, 2020, filed with the SEC in the fourth quarter of 2020. In addition to the risks described above and in Entera's annual report on Form 20–F and current reports on Form 6–K and other filings with the SEC, other unknown or unpredictable factors also could affect Entera's results. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated in such forward–looking statements and estimates will be achieved.

All written and verbal forward–looking statements attributable to Entera or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Entera cautions investors not to rely too heavily on the forward–looking statements Entera makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Entera undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise.

Contact:

Jonathan Lieber, CFO
Tel: +001 617–362–3579
jon@enterabio.com


GLOBENEWSWIRE (Distribution ID 8123273)

Conagen Begins Scale Up of Natural Sustainable Musk Macrocyclic Lactone Fragrance Materials

Bedford, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) — Conagen announced today its breakthrough development in the commercial production of natural and sustainable macrocyclic musk lactones from natural substrates using its proprietary technology, further expanding its already extensive gamma–lactone portfolio.

Musk fragrance compounds are typically used as base note ingredients in perfumes. The natural sources of these compounds are found in glandular secretions of animals, such as musk deer and some plants. In low concentrations, musks are expansive, velvety, sensual and sweet. However, the fragrance industry overall has moved away from animal sources, and plant sources are scarce. Currently, chemically synthesized substitutes with similar scents are available for use.

Conagen successfully bridged its gamma–lactone production technology with its lipid platform to expand its lactone portfolio to natural musk scent macrocyclic lactones.

Built upon the diversity of structures among natural lipids, Conagen's macrocyclic musk portfolio contains diverse compounds representing a range of familiar and novel aromas, many of which have never before been commercially available. This variety of characteristics creates a wider spectrum of fragrance application options for manufacturers that use musk macrocyclic lactones in their products.

“The expansion of Conagen's lactone platform to macrocyclic lactones with musk fragrances adds to our momentum in meeting consumers' demand for nature–based, clean ingredients,” said Dr. Casey Lippmeier, VP of innovation at Conagen.

“We have found new ways to make various classes of natural lactones. I am excited by the new prospects our musk lactones bring as they have grown rapidly from a proof–of–concept technology to commercial production. Expect many more innovative, natural lactones coming from our technology,” said Dr. Lippmeier.

For the last 10 years, Conagen has successfully developed one of the largest portfolios of ingredient products for its customers, including science–based Blue California ingredients.

"The technology breakthrough is impressive on its own, but equally so is the speed at which Conagen was able to take musk from idea to scaleup "" five short months. That's the partner you want to have in these competitive markets," said Kathy Oglesby, head of flavor and fragrance at Blue California.

###

About Conagen

Conagen is making the impossible possible. Our scientists and engineers use the latest synthetic biology tools to develop sustainable, nature–based molecules bio–manufactured into the highest quality products available. We focus on the bioproduction of high–value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. For more information, visit www.conagen.com

Attachments


GLOBENEWSWIRE (Distribution ID 8123553)

Appear Inc to launch World’s Lightest and First Graphene Battery-powered 5G Smartphone

SAN FRANCISCO, Jan. 07, 2021 (GLOBE NEWSWIRE) — Appear Inc. announced the launch of the world's lightest and first graphene battery–powered smartphone with innovative water–resistant technology. There is already a lot of interest in this smartphone. Appear has begun receiving orders and projections call for a million units sold in the first six months. The smartphone would be available in stores and major online retailers by March 2021.

Appear is a technology company already known for its innovative electronic products. The company is based in San Francisco and also operates internationally in countries such as Singapore, UAE, Hong Kong and India. Appear specializes in developing B2B IoT innovations. The company created many innovative technologies such as smartphones, graphene fast–charge battery applications, buoyant and levitating speakers.

Appear Has Partnered With Foxconn for Manufacturing

To meet growing demands, Appear has partnered with Foxconn India for its manufacturing needs. Foxconn is a well–known and trusted manufacturer for many popular brands of smartphones and consumer electronic products. It has the experience, expertise and facilities to meet Appear's high–quality standards.

Graphene Fast–Charge

Appear has always been driven to create innovative products using advanced material science. Its new smartphone exemplifies this mindset. The phone is powered with Qualcomm processors. Appear is known for its Graphene Super 20 Power Bank, which recharges fully in 20 minutes using Appear's proprietary Fast Charge battery technology. Now, this proprietary technology is successfully integrated in a smartphone.

Graphene, similar to graphite, is composed purely of carbon. It has revolutionized many areas of manufacturing due to its unique properties. Though it is stronger than steel, graphene is lightweight and one of the most conductive materials. This allows graphene to act as a super capacitor for Appear's revolutionary Fast Charge Technology. Graphene–enhanced Li–ion batteries have longer lifespans, higher capacities and faster charging times while remaining flexible and light.

The Smartphone Is Complete With Innovative Technology

One of the most exciting features of the new smartphone is its water–resistant technology. Every year, 11% of smartphones are damaged by water. That amounts to 165 million phones per year or 452,000 per day! As consumers become more dependent on their smartphones, water protection has become a necessary feature. Building more resilient phones will also help reduce growing electronic waste. This new smartphone is the perfect option for the eco–conscious consumer.

The smartphone also includes Appear's proprietary mobile applications. These apps will be pre–installed into the product.

Designed by the Same Company That Built Buoyant and Levitating Speakers

The water–resistant technology uses advanced material science. Appear first debuted the technology in its Buoyant Speakers. Those speakers have already proven the water–resistant properties in pools across the world. However, the real show–stopper has been Appear's levitating speakers. When powered, the speaker raises and hovers over the speaker box. These amazing speakers deliver both a song and a show!

This levitating technology can be deployed in many different industries such as home automation, sports and the automotive industry. Appear has plans to license the technology across many industries and countries.

The Appear Smartphone Will Be Available in March 2021

Appear is expecting high consumer demand, so the company has partnered with popular retailers like Amazon and one of the largest distributors in the MENA region –Sharaf DG and many more e–tailers. The company will be working with 70+ distributors to ensure its smartphones are available globally. They are expected to be available in March 2021. You can visit Appear to sign up for update notifications.


GLOBENEWSWIRE (Distribution ID 8121980)

Germany’s BfArM Joins SNOMED International for Nationwide Use of SNOMED CT

LONDON, Jan. 06, 2021 (GLOBE NEWSWIRE) — Germany's Federal Institute for Drugs and Medical Devices (BfArM) has announced their membership in SNOMED International for national use of SNOMED CT from the beginning of January 2021.

SNOMED CT, the world's most comprehensive clinical terminology and a recognized critical element for the electronic exchange of health data, is an important building block to achieve Germany's digitization initiative. Effective January 1, 2021, German users can register to request a free license for use of SNOMED CT by visiting the BfArM's National Release Center website.

BfArM President Prof. Dr. Karl Broich shares, "with SNOMED CT, the digitization of the healthcare system in Germany continues. As an international standardized health terminology, SNOMED CT is an important prerequisite for the reliable use and exchange of medical data from various sources to enable clinical and research activities. This is how we accelerate innovative developments and deliver new types of care options more quickly to patients."

Not all users in Germany will be new to SNOMED CT. In 2020, the Federal Ministry of Education and Research initiated a pilot license with a limited number of sub–licenses for Medical Informatics Initiative research participants and partners, an endeavor led by the TMF. Additionally, SNOMED International and Germany have, over the years, arranged for limited public good licenses allowing German clinicians, researchers and academics to experience the power of SNOMED CT. Now with full membership, all German institutions and specialist groups involved in the health care sector wishing to use SNOMED CT in their applications can apply for a free license from the BfArM.

Founded in 2007 by nine charter nations, SNOMED International is a not–for–profit organization that owns and maintains SNOMED CT, the world's most comprehensive clinical terminology. With over 350,000 concepts, SNOMED CT is not just a coding system of diagnosis. It also covers clinical findings like signs and symptoms and tens of thousands of surgical, therapeutic and diagnostic procedures. Also within the scope of SNOMED CT are observables and those concepts representing body structures, organisms, substances, pharmaceutical products, physical objects, physical forces, specimens, etc. needed to be recorded in or around the health record.

With SNOMED CT, users can record patient data more accurately, exchange patient data both within the health care team and with patients, both locally and across borders, to improve patient outcomes. Further, SNOMED CT can be used in health data and analytics platforms for clinical analytics, population analytics, management analytics, clinical research, applied research, and other research activities to improve health care.

SNOMED International CEO Don Sweete recognizes the dedication and work Germany has committed to formally begin their SNOMED CT journey. "With our global circumstance, 2021 is a year to showcase the power delivered by digital health," Don says. "Furthering Germany's digital health goals, SNOMED International membership will enable German users nationally to take advantage of augmented content areas such as Social Care and Social Determinants of Health, Genomics, Vaccines, and Devices. Due to SNOMED CT's polyhierarchical structure, Germany will be able to leverage SNOMED CT to engage in leading edge research and data analytics."

SNOMED International is proud to now work with 22 Members across Europe, and 40 Members globally. The addition of Germany to the organization further extends the reach of interoperable patient health information across Europe and broadens mature use of SNOMED CT to support German care delivery and clinical research.

For more information, please visit SNOMED International or the BfArM SNOMED CT website.

Media Contact:

Kelly Kuru
SNOMED International | Chief Communications Officer
(e) comms@snomed.org


GLOBENEWSWIRE (Distribution ID 8121478)

Germany’s BfArM Joins SNOMED International for Nationwide Use of SNOMED CT

LONDON, Jan. 06, 2021 (GLOBE NEWSWIRE) — Germany's Federal Institute for Drugs and Medical Devices (BfArM) has announced their membership in SNOMED International for national use of SNOMED CT from the beginning of January 2021.

SNOMED CT, the world's most comprehensive clinical terminology and a recognized critical element for the electronic exchange of health data, is an important building block to achieve Germany's digitization initiative. Effective January 1, 2021, German users can register to request a free license for use of SNOMED CT by visiting the BfArM's National Release Center website.

BfArM President Prof. Dr. Karl Broich shares, "with SNOMED CT, the digitization of the healthcare system in Germany continues. As an international standardized health terminology, SNOMED CT is an important prerequisite for the reliable use and exchange of medical data from various sources to enable clinical and research activities. This is how we accelerate innovative developments and deliver new types of care options more quickly to patients."

Not all users in Germany will be new to SNOMED CT. In 2020, the Federal Ministry of Education and Research initiated a pilot license with a limited number of sub–licenses for Medical Informatics Initiative research participants and partners, an endeavor led by the TMF. Additionally, SNOMED International and Germany have, over the years, arranged for limited public good licenses allowing German clinicians, researchers and academics to experience the power of SNOMED CT. Now with full membership, all German institutions and specialist groups involved in the health care sector wishing to use SNOMED CT in their applications can apply for a free license from the BfArM.

Founded in 2007 by nine charter nations, SNOMED International is a not–for–profit organization that owns and maintains SNOMED CT, the world's most comprehensive clinical terminology. With over 350,000 concepts, SNOMED CT is not just a coding system of diagnosis. It also covers clinical findings like signs and symptoms and tens of thousands of surgical, therapeutic and diagnostic procedures. Also within the scope of SNOMED CT are observables and those concepts representing body structures, organisms, substances, pharmaceutical products, physical objects, physical forces, specimens, etc. needed to be recorded in or around the health record.

With SNOMED CT, users can record patient data more accurately, exchange patient data both within the health care team and with patients, both locally and across borders, to improve patient outcomes. Further, SNOMED CT can be used in health data and analytics platforms for clinical analytics, population analytics, management analytics, clinical research, applied research, and other research activities to improve health care.

SNOMED International CEO Don Sweete recognizes the dedication and work Germany has committed to formally begin their SNOMED CT journey. "With our global circumstance, 2021 is a year to showcase the power delivered by digital health," Don says. "Furthering Germany's digital health goals, SNOMED International membership will enable German users nationally to take advantage of augmented content areas such as Social Care and Social Determinants of Health, Genomics, Vaccines, and Devices. Due to SNOMED CT's polyhierarchical structure, Germany will be able to leverage SNOMED CT to engage in leading edge research and data analytics."

SNOMED International is proud to now work with 22 Members across Europe, and 40 Members globally. The addition of Germany to the organization further extends the reach of interoperable patient health information across Europe and broadens mature use of SNOMED CT to support German care delivery and clinical research.

For more information, please visit SNOMED International or the BfArM SNOMED CT website.

Media Contact:

Kelly Kuru
SNOMED International | Chief Communications Officer
(e) comms@snomed.org


GLOBENEWSWIRE (Distribution ID 8121478)

LeddarTech Announces the Appointment of Carl-Peter Forster to Its Board of Directors

QUEBEC CITY, Jan. 06, 2021 (GLOBE NEWSWIRE) — LeddarTech , a global leader in Level 1–5 ADAS and AD sensing technology, is pleased to announce the appointment of Carl–Peter Forster to the Board of Directors, which further enhances the diversity and experience of the Board.

Carl–Peter Forster holds a degree in economics from Bonn University and a degree in aviation and space technology from the Technical University in Munich, Germany.

Carl–Peter has an extensive senior management background in the automotive industry with brands including BMW AG, in Munich, where he held various positions including Vice–President. He was also Managing Director of BMW South Africa, and a member of the board of BMW AG, responsible for global manufacturing, until 2000. Between 2001 and 2009, Carl–Peter was Managing Director of Adam Opel AG, then from 2006 President and CEO of General Motors Europe and a member of GM's Global Automotive Strategy board. From 2010 to 2011, he was Group CEO of Tata Motors (which included Jaguar Land Rover).

Since 2013, Carl–Peter has been a special advisor to the Chairman of the Geely Group, also holding board positions at Volvo Cars Group in Gothenburg (Sweden), Geely Automobile Holdings Ltd. (Hong Kong), as well as CEVT (the Geely engineering center in Gothenburg), and Chairman of The London Electric Vehicle Company (formerly The London Taxi Company) until 2019. In addition to serving as a board member for LeddarTech, Carl–Peter is currently Chairman of Chemring Plc, Chairman of the Shareholder Committee of Hella KGaA, and a member of the boards of IMI Plc, Babcock Plc, The Mobility House AG, Gordon Murray Design Ltd., Kinexon GmbH, Clear Motion Ltd., and Envisics Ltd.

"The LeddarTech Board of Directors is very pleased to welcome Carl–Peter Forster to the LeddarTech team", stated Mr. Michel Brl, chairman of the Board of LeddarTech. "Carl–Peter brings with him a wealth of industry experience as a leader with some of the world's largest automotive companies. Carl–Peter's extensive experience in the automotive industry as well as in ADAS and AD technology companies will be a tremendous asset to LeddarTech," Mr. Brl concluded.

About LeddarTech

LeddarTech is a leader in environmental sensing platforms for autonomous vehicles and advanced driver assistance systems. Founded in 2007, LeddarTech has evolved to become a comprehensive end–to–end environmental sensing company by enabling customers to solve critical sensing and perception challenges across the entire value chain of the automotive and mobility market segments. With its LeddarVision sensor–fusion and perception platform and its cost–effective, scalable, and versatile LiDAR development solution for automotive–grade solid–state LiDARs based on the LeddarEngine, LeddarTech enables Tier 1–2 automotive system integrators to develop full–stack sensing solutions for autonomy level 1 to 5. These solutions are actively deployed in autonomous shuttle, truck, bus, delivery vehicle, smart city/factory, and robotaxi applications. The company is responsible for several innovations in cutting–edge automotive and mobility remote–sensing applications, with over 95 patented technologies (granted or pending) enhancing ADAS and autonomous driving capabilities.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook, and YouTube.

Contact:
Daniel Aitken, Vice–President, Global Marketing, Communications, and Product Management, LeddarTech Inc.
Tel.: + 1–418–653–9000 ext. 232
daniel.aitken@leddartech.com

Leddar, LeddarTech, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, VAYADrive, VayaVision, and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names, and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.


GLOBENEWSWIRE (Distribution ID 8120228)

INVNT Continues Commitment To EMEA-Based Clients with New Executive Creative Director

LONDON, UK, Jan. 05, 2021 (GLOBE NEWSWIRE) — INVNT. The global live brand storytelling agency today announces the appointment of Neil Mason to the role of Executive Creative Director, EMEA. Mason brings more than 20 years' experience to the role, over which he has led the creative output of experiential and integrated campaigns for brands including Nike, McLaren, Samsung, Google and Cisco.

Based in London, Mason joins from Identity Group where he was Executive Creative Director, and has held senior creative positions at agencies including George P. Johnson and Jack Morton Worldwide. Throughout the course of his career, he has managed and grown creative departments, elevated existing projects to achieve strategic business goals, and won new business across all sectors.

A judge of the internationally recognised D&AD Awards since 2018, guest lecturer at the Royal College of Art in London, and member of the board of governors at Ravensbourne University, Mason is not only passionate about his craft, but about educating and inspiring the next generation of creative talent.

Mason will report into Stephenson, and his first day is 5 January 2021.

Commenting on the appointment, Kristina McCoobery, CEO, INVNT said: “Our growth strategy has always been aligned with the ever–evolving needs of our clients, and the decision to expand INVNT's EMEA footprint is a direct result of the increased demand for our services here. Being a creative and strategic–led business, we recognised the need to recruit a leading creative for the region, so that we could continue to support clients in not just achieving but exceeding their campaign goals.”

Stephenson explained: “It was important we find an out–of–the–box thinking individual who embodies INVNT's challenger mentality in both their portfolio of work and ethos, and without a doubt, Neil ticks these boxes. An ideas guy through and through, at INVNT Neil will lean on his proven experience to devise unique concepts for virtual, hybrid and in–person experiences, across all mediums. While EMEA focused and based, he will also collaborate with our wider creative team on global campaigns which are localised in region. We're thrilled to have Neil spearheading the creative team!”

Mason added: “INVNT employees describe themselves as "wicked smart teenagers,' and I can see why. I've been blown away by the agency's ability to challenge themselves and their clients to push the boundaries and deliver great work at a time when in–person experiences haven't been possible. I'm honoured to now call myself a "wicked smart teenager'! I look forward to collaborating with the team and our clients to create experiences so unique and relevant, they cause brand messages to strike, stick and spread amongst their audiences, even at a time when the world around us is changing so rapidly.”

###

About INVNT
Founded in 2008 by Scott Cullather and Kristina McCoobery, INVNT uses the craft of live brand storytelling to create and produce live experiences that excite and unite physical and virtual audiences, globally. The company's "challenge everything' positioning statement helps clients including General Motors, Grant Thornton, Merck, PepsiCo and Samsung share their stories with every audience that matters. Part of [INVNT GROUP], THE GLOBAL BRANDSTORY PROJECT, INVNT's offices are strategically located in New York, London, Sydney, Detroit, San Francisco, Washington D.C., Stockholm and Singapore. For more information visit www.invnt.com

Attachment


GLOBENEWSWIRE (Distribution ID 8120675)

First US patient implanted in the DREAM pivotal IDE study, with the Genio® system for the treatment of Obstructive Sleep Apnea (OSA)

PRESS RELEASE

First US patient implanted in the DREAM pivotal IDE study, with the Genio system for the treatment of Obstructive Sleep Apnea (OSA)
DREAM is a pivotal, Investigational Device Exemption (IDE) study, designed to support marketing authorization in the United States

Mont–Saint–Guibert, Belgium "" 5th January 2021 "" Nyxoah S.A. (EBR: NYXH) ("Nyxoah" or the "Company"), a health–technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the successful implantation of the first US patient in the DREAM pivotal IDE study. The implantation took place at the Nose and Sinus Institute Boca Raton, Florida and was performed by Dr. Melyssa Hancock, Otolaryngology–Head & Neck surgeon.

The DREAM (Dual–sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea) study is a pivotal, Investigational Device Exemption (IDE) trial designed to support the marketing authorization of the Genio system in the United States. This multicenter, prospective, open–label, observational study will enroll 134 patients, who will undergo the implantation procedure in up to 26 centers worldwide including sites in the United States, Germany, Belgium and Australia.

Dr. Melyssa Hancock, implanting surgeon from the Nose and Sinus Institute Boca Raton commented: " We are very excited to be chosen as the first center in the United States to implant the Genio system in a patient for treatment of obstructive sleep apnea. The teaming of the Nose and Sinus Institute of Boca Raton with the innovators at Nyxoah represents the collaboration of some of the most experienced surgeons in the United States today treating nose and airway issues with a team of brilliant international engineers. During this time of COVID–19 and virtual adaptation to everything we do, the fact that we were able to communicate in real–time during the procedure with other surgeons globally who have extensive experience with this device made it a truly extraordinary and successful endeavor."

Olivier Taelman, Chief Executive Officer of Nyxoah, added: "I'm really proud of Nyxoah's team reaching another key milestone despite all challenges due to the Covid–19 pandemic and would like to congratulate Dr. Hancock and her team for implanting the first US patient with the Genio system. Enabling US physicians to build their experience with the Genio system, combined with the existing expertise of other international surgeons participating in the DREAM study, is supporting Nyxoah's timeline for the pivotal IDE study enrollment closing by the end of Q2 2021.

– ENDS –

For further information, please contact:

Nyxoah
Milena Venkova, Corporate Communications Manager
milena.venkova@nyxoah.com
+32 490 11 93 57

About Nyxoah

Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a CE–validated, patient–centered, next generation hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk1 and comorbidities including cardiovascular diseases, depression and stroke.
Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio system received its European CE Mark in 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, the DREAM IDE pivotal study for FDA approval and a post–marketing EliSA study in Europe to confirm the long–term safety and efficacy of the Genio system.
For more information, please visit www.nyxoah.com.

Caution "" CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

1 Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen–Year Follow–up of the Wisconsin Sleep Cohort, Sleep. 2008 Aug 1; 31(8): 1071""1078.


GLOBENEWSWIRE (Distribution ID 1000449009)